Mednet Logo
HomeRadiation Oncology
Radiation Oncology

Radiation Oncology

Expert insights on radiation treatment planning, techniques, toxicity management, and multimodal cancer care.

Recent Discussions

Is it necessary to treat the entire larynx with intermediate or elective dose in a T1/T2 squamous cell carcinoma of the supraglottic or subglottic larynx?

1
4 Answers

Mednet Member
Mednet Member
Radiation Oncology · University of Florida

It would be hard to miss it without missing your target. Additionally, you have level 6 nodes with the subglottis and levels 2-4 with the supraglottis. Not a great idea. To clarify, don’t try to spare the glottis.

Is it feasible to treat central liver tumors +/- portal vein thrombus with SBRT while minding central hepatobiliary tract constraints?

1
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Memorial Sloan-Kettering Cancer Center

Remember that biliary strictures frequently cause death in these patients because stents don't always drain after these high doses of radiation. I have personally never caused a biliary stricture. The regimens that I am using with an SBRT technique are below the threshold for biliary stricture and r...

When is it appropriate to recommend SBRT directed to sites of oligometastasis (ex, single adrenal met) for a patient with extensive stage small cell s/p chemo and PCI?

8
4 Answers

Mednet Member
Mednet Member
Radiation Oncology · Northeast Alabama Regional Medical Center

May I play devil's advocate for one moment? I don't wholly disagree with @Dr. First Last btw, fwiw.1) Some people with SCLC can be cured. It appears that the application of a local therapy in limited stage SCLC increases the chance for long-term DFS (aka "a cure"). Five-year survival was doubled fro...

Have the results of the OPRA trial influenced your decision to recommend long course chemoradiation vs short course radiation therapy for patients receiving TNT who intend to undergo surgery?

7
4 Answers

Mednet Member
Mednet Member
Radiation Oncology · Memorial Sloan-Kettering Cancer Center

The TME-free survival rate in the OPRA trial has solidified chemoradiation followed by consolidative chemotherapy as a standard in our practice. However, since the principal investigator is at our institution, it just meant that we continued doing what we were doing. It is important to realize that ...

How do you approach prostate cancer patients who have hypertestosteronism on pre-treatment labs?

1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Levine Cancer Institute

This is rare and full disclosure - I have not personally experienced this situation and this answer is based on discussion with colleagues. I suspect whatever the true incidence is, it is likely detected in only a fraction of patients as ADT is often initiated without drawing testosterone levels, an...

How do you avoid epilation in patients hoping to preserve their facial hair during radiotherapy?

4
5 Answers

Mednet Member
Mednet Member
Radiation Oncology · University of Iowa

Interesting question. I have not created an avoidance. It’s my experience that doses of about 50 Gy+ commonly cause permanent hair loss. It’s hard to avoid hair loss in areas where elective nodal or mucosal/skin coverage is needed. It’s certainly disappointing for some patients. In many scenarios of...

How would you treat a schwannoma of the breast with a positive margin that is not amenable to re-excision?

1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Varian Medical Systems/Allegheny health network

If it's pure schwannoma, it's benign pathology, and I would not do anything for microscopic residual disease.

How do you approach brain SRS for patients currently receiving Trastuzumab deruxtecan with progressive brain lesions?

3
4 Answers

Mednet Member
Mednet Member
Radiation Oncology · University of Alabama at Birmingham

Trastuzumab deruxtecan is an antibody drug conjugate targeting HER2 cells. This agent has recently been compared to a similar antibody drug conjugate T-DM1 (Kadcyla) and was found to improve disease progression and lower the risk of death for patients with relapsed HER2 metastatic breast cancer (Cor...

Would you ever recommend testosterone replacement for men with incomplete T recovery after ADT for prostate cancer?

3
5 Answers

Mednet Member
Mednet Member
Radiation Oncology · University of Miami Miller School of Medicine

I have been hesitant to agree to supplemental testosterone after prostate cancer treatment, especially within the first few years. Prostate biopsies during that time often show atypical cells that are suspicious or adenocarcinoma with treatment effect. Androgens are pro-survival and the full effects...

When do you refer patients receiving CNS-directed radiotherapy to endocrinology?

1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Mayo Clinic

In my practice, patients with pituitary tumors are followed by a pituitary endocrinologist. For all the other skull based tumors, I usually don’t refer patients to endocrinology unless a patient is found to have abnormalities with their pituitary function tests. We screen most patients with skull ba...